Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2006 2
2007 5
2008 2
2012 1
2013 4
2014 4
2015 8
2016 5
2017 4
2018 4
2021 2
2022 2
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Breast cancer in China.
Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Fan L, et al. Among authors: strasser weippl k. Lancet Oncol. 2014 Jun;15(7):e279-89. doi: 10.1016/S1470-2045(13)70567-9. Lancet Oncol. 2014. PMID: 24872111 Review.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Endometrial Cancer in Brazil: Preparing for the Rising Incidence.
Paulino E, Nogueira-Rodrigues A, Goss PE, Faroni L, Guitmann G, Strasser-Weippl K, Bukowski A. Paulino E, et al. Among authors: strasser weippl k. Rev Bras Ginecol Obstet. 2018 Oct;40(10):577-579. doi: 10.1055/s-0038-1673644. Epub 2018 Oct 23. Rev Bras Ginecol Obstet. 2018. PMID: 30352454 Free PMC article.
Aromatase inhibitors for chemoprevention.
Goss PE, Strasser-Weippl K. Goss PE, et al. Among authors: strasser weippl k. Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):113-30. doi: 10.1016/s1521-690x(03)00070-8. Best Pract Res Clin Endocrinol Metab. 2004. PMID: 14687601 Review.
New Perspectives in the Management of Triple-Negative Breast Cancer.
Bartsch R, Bago-Horvath Z, Egle D, Gampenrieder SP, Grünberger B, Heibl S, Marhold M, Preuss C, Rinnerthaler G, Strasser-Weippl K, Suppan C, Singer CF, Gnant M. Bartsch R, et al. Among authors: strasser weippl k. Breast Care (Basel). 2025 Aug 15. doi: 10.1159/000547988. Online ahead of print. Breast Care (Basel). 2025. PMID: 41063764 Free PMC article. Review.
Improving access to high-cost cancer drugs in Latin America: Much to be done.
Ruiz R, Strasser-Weippl K, Touya D, Herrero Vincent C, Hernandez-Blanquisett A, St Louis J, Bukowski A, Goss PE. Ruiz R, et al. Among authors: strasser weippl k. Cancer. 2017 Apr 15;123(8):1313-1323. doi: 10.1002/cncr.30549. Epub 2017 Feb 9. Cancer. 2017. PMID: 28182258 Free article. Review.
Breast cancer in Colombia: a growing challenge for the healthcare system.
Duarte C, Salazar A, Strasser-Weippl K, de Vries E, Wiesner C, Arango-Gutiérrez A, Krush L, Goss PE. Duarte C, et al. Among authors: strasser weippl k. Breast Cancer Res Treat. 2021 Feb;186(1):15-24. doi: 10.1007/s10549-020-06091-6. Epub 2021 Feb 21. Breast Cancer Res Treat. 2021. PMID: 33611666 Review.
45 results